Why the study?
Does ticagrelor improve outcomes in patients across the spectrum of atherothrombotic disease?
Does ticagrelor improve outcomes in patients across the spectrum of atherothrombotic disease?
The PARTHENON clinical development program evaluates ticagrelor across a broad spectrum of atherothrombotic diseases, with established benefits in ACS and prior MI, and ongoing trials in stroke, PAD, and CAD with diabetes.
Confirms ticagrelor benefit in ACS and prior MI; leaves open extension across broader atherothrombotic spectrum.
Ticagrelor (P2Y12 receptor antagonist) is presently indicated for preventing atherothrombotic events in patients with acute coronary syndrome and patients with a history of myocardial infarction. The PARTHENON clinical development program comprises five randomized, controlled, cardiovascular, indication-seeking outcome studies, aiming to evaluate ticagrelor across the spectrum of patients with atherothrombotic disease. Results of two large-scale trials support a benefit for ticagrelor in patients with acute coronary syndrome (PLATO; ClinicalTrials.gov: NCT00391872) and in patients with a history of myocardial infarction (PEGASUS-TIMI 54; ClinicalTrials.gov: NCT01225562). Ongoing trials will provide information on the efficacy and safety of ticagrelor in patients with acute ischemic stroke or transient ischemic attack (SOCRATES; ClinicalTrials.gov: NCT01994720), peripheral artery disease (EUCLID; ClinicalTrials.gov: NCT01732822) and coronary artery disease in patients with Type 2 diabetes mellitus (THEMIS: ClinicalTrials.gov: NCT01991795).
No takes yet. Share an insight, caveat, or question.
Held et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: